Target / Biomarker
Discovery & Validation
Euretos is an AI (Artificial Intelligence) platform used by pre-clinical researchers for in-silico discovery & validation of targets and biomarkers. World leading pharma, biotech and academic institutions use it to accelerate their research. Available as subscription, consulting service or direct access
EURETOS AI PLATFORM
In Silico Multi Omics
Drive your in vitro and in vivo research by in silico multi omics analysis. Ask Euretos and evaluate how molecular mechanisms influence cell and tissue functions, and in turn mediate phenotypes and disease pathology.
FIND OUT MORE
Literature monitoring by Euretos detects over 550 ‘first ever’ gene-cancer mentions in Pubmed each monthFriday 14 December 2018
In a recent study published in Cellular SIgnalling, researchers identified MAP2K6 (also known as MKK6) as a novel potential target for Esophageal adenocarcinoma (EAC), an aggressive form of cancer with a 5-year survival rate of less than 15%. As pa ...
Kees Albers PhD joins Euretos as Chief Science OfficerFriday 02 November 2018
UTRECHT SCIENCE PARK - Euretos, a leading AI provider for in silico target and biomarker discovery, announced today that Kees Albers, Ph.D., has joined its leadership team as Chief Scientific Officer.Prior to joining Euretos, Kees was assistant pro ...
Prof David Webb (The Scripps Research Institute)
“The Euretos AI Platform is nothing less than an in silico way to save all drug and biotech researchers an infinite amount of blood, sweat and tears by providing
them with a powerful knowledge discovery platform.
The Euretos AI Platform allows the researcher to rapidly assess whether a given target, research area, etc., is related, even distantly, to another such entity thus allowing one to uncover hidden connections, leading to new knowledge.In the drug discovery arena, this thing is a gold mine.